Published in Can J Infect Dis Med Microbiol on August 30, 2016
CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control (2008) 24.70
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control (2004) 14.85
NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol (2008) 13.49
Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis (2005) 9.06
The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs (2007) 3.63
Nosocomial infections and multidrug-resistant organisms in Germany: epidemiological data from KISS (the Hospital Infection Surveillance System). Dtsch Arztebl Int (2011) 3.02
National nosocomial infections surveillance system (NNIS): description of surveillance methods. Am J Infect Control (1991) 3.00
National Healthcare Safety Network (NHSN) report, data summary for 2012, Device-associated module. Am J Infect Control (2013) 1.70
Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med (2006) 1.47
Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clin Microbiol Infect (2005) 1.32
Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother (2005) 1.30
Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis (2001) 1.28
Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother (2002) 1.23
Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist (2005) 1.18
National Healthcare Safety Network report, data summary for 2013, Device-associated Module. Am J Infect Control (2015) 1.13
Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb Drug Resist (2011) 1.01
Risk factors for recovery of imipenem- or ceftazidime-resistant pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol (2006) 0.99
Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality. Medicina (Kaunas) (2010) 0.95
Lowbury Lecture 2008: infection control and limited resources--searching for the best solutions. J Hosp Infect (2009) 0.95
Imipenem-resistant Pseudomonas aeruginosa infection at a medical-surgical intensive care unit: risk factors and mortality. J Crit Care (2009) 0.91
Infection control practice in countries with limited resources. Ann Clin Microbiol Antimicrob (2011) 0.91
Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections. J Korean Med Sci (2008) 0.91
Device-associated infection rates and bacterial resistance in six academic teaching hospitals of Iran: Findings from the International Nocosomial Infection Control Consortium (INICC). J Infect Public Health (2015) 0.91
Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol (2009) 0.91
Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect (2005) 0.90
Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. Am J Infect Control (2009) 0.89
Susceptibility patterns and cross resistances of antibiotics against Pseudomonas aeruginosa in a teaching hospital of Turkey. Ann Clin Microbiol Antimicrob (2002) 0.89
Surveillance and correlation of antimicrobial usage and resistance of Pseudomonas aeruginosa: a hospital population-based study. PLoS One (2013) 0.89
Prevalence of nosocomial infections at intensive care units in Turkey: a multicentre 1-day point prevalence study. Scand J Infect Dis (2004) 0.89
The categorization of prior antibiotic use: impact on the identification of risk factors for drug resistance in case control studies. Am J Infect Control (2007) 0.86
Factors associated with acquisition of Pseudomonas aeruginosa resistant to gentamicin. Am J Med Sci (1978) 0.84
Mandatory public reporting of healthcare-associated infections in developed countries: how can developing countries follow? J Hosp Infect (2015) 0.80
Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 0.79
Nosocomial infections with ceftazidime-resistant Pseudomonas aeruginosa: risk factors and outcome. Infect Control Hosp Epidemiol (1999) 0.79
[Risk factors of nosocomial infections caused by piperacillin-tazobactam resistant Pseudomonas aeruginosa]. Srp Arh Celok Lek (2013) 0.77
Nosocomial acquisition of Pseudomonas aeruginosa resistant to both ciprofloxacin and imipenem: a risk factor and laboratory analysis. Eur J Clin Microbiol Infect Dis (2008) 0.77